Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Leflunomide: a manageable safety profile.

Peit L C M van Riel1, Josef S Smolen, Paul Emery

  • 1Department of Rheumatology, University Medical Centre Nijmegen, Nijmegen, The Netherlands.

The Journal of Rheumatology. Supplement
|June 2, 2004
PubMed
Summary

Leflunomide, a disease-modifying antirheumatic drug, demonstrates a manageable safety profile for rheumatoid arthritis treatment. Common side effects like diarrhea and rash are often dose-related and diminish with continued use.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chasing the target: reports from the Advances in Targeted Therapies meeting, 2025.

Annals of the rheumatic diseases·2026
Same author

Chasing the target: reports from the Advances in Targeted Therapies meeting, 2024.

Annals of the rheumatic diseases·2025
Same author

Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023.

Annals of the rheumatic diseases·2023
Same author

[80 milestones in rheumatology from 80 years- III. 1980-2000].

Zeitschrift fur Rheumatologie·2021
Same author

Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD.

RMD open·2019
Same author

Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations.

RMD open·2019

Area of Science:

  • Rheumatology
  • Pharmacovigilance

Background:

  • Leflunomide is a disease-modifying antirheumatic drug (DMARD) used for rheumatoid arthritis.
  • Its safety profile is established through clinical trials, postmarketing surveillance, and epidemiological studies.

Purpose of the Study:

  • To provide a precise representation of leflunomide's adverse event incidence under real-world conditions.
  • To assess the manageability of leflunomide-associated adverse events.

Main Methods:

  • Review of clinical trial data.
  • Analysis of postmarketing surveillance data.
  • Evaluation of epidemiological studies.

Main Results:

  • Leflunomide's safety profile is consistent across different study types and comparable to other DMARDs.

Related Experiment Videos

  • Common adverse events include diarrhea, elevated liver enzymes, alopecia, and rash.
  • Most experts (95%) consider these adverse events manageable.

    • Conclusions:

    • Leflunomide exhibits a manageable safety profile in rheumatoid arthritis treatment.
    • Adverse events can often be managed by dose reduction, symptomatic treatment, or drug discontinuation and re-challenge.
    • Patient education and involvement in management are crucial for addressing side effects.